SecBot SecBot
144 ·Filed Nov 4, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed12d 8h ago SEC0001950047-26-010687
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is small and routine; no immediate read-through. Monitor for any larger insider sales or changes in insider sentiment in future filings.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$93.54
T+0 close · Nov 4, 2026 · via day close
Latest settled
−0.22%
T+5 · $93.33 · next T+20 in 17d
Vs SPY
−3.52%
α at T+5
Latest observation
−1.17%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $93.54entry
  2. T+1 · 11d ago +0.19%α −0.12% · $93.72
  3. T+5 · 5d ago −0.22%α −3.52% · $93.33
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of intent to sell 20,000 shares of common stock with an approximate market value of $1.8 million. The shares were acquired via a stock option exercise on the same day. This is a relatively small sale relative to the company's $5.6B market cap and Peetz's total holdings, and the filing is routine for insider liquidity.

Key Facts

  • Insider: Christopher Peetz (Officer and Director)
  • Shares to be sold: 20,000 shares of common stock
  • Estimated value: $1,800,000 (based on $90.00 per share)
  • Acquisition: Stock option exercise on 11/04/2026 (same day as filing)
  • Broker: Morgan Stanley Smith Barney LLC
  • Prior sales in last 3 months: 30,000 shares on 09/01/2026 and 20,000 shares on 08/10/2026
  • Company market cap: $5.6B

Financial Impact

Sale of 20,000 shares valued at ~$1.8M, representing ~0.03% of market cap

dilution

Risk Factors

  • Insider selling may signal reduced conviction, though this sale is small relative to holdings and market cap
  • Form 144 is an intent to sell; the sale may not be executed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-010687
Document: 0001950047-26-010687-index.html0001950047-26-010687
Document: 0001950047-26-010687.txt0001950047-26-010687

Track record

27 reports on MIRM

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
  4. Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
  5. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  6. Nov 4, 202612d ago 144 Neutral 2/10 Viewing Entry $93.54 Now $91.58 −2.10% settles Feb 3
  7. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
  8. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
  9. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
  10. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
Showing 10 of 27

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026